Evidence map›Paper›PMID 29895640›Full record

ArticlemBio2018

A Single-Cell Approach to the Elusive Latent Human Cytomegalovirus Transcriptome.

Felicia Goodrum, Shannon McWeeney

Open access · goldAbstract readComment
In one paragraph

Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Felicia GoodrumUniversity of Arizona, Tucson, Arizona, USA fgoodrum@email.arizona.edu.
Shannon McWeeneyOregon Health and Sciences University, Portland, Oregon, USA.
Oregon Health & Science University · USUniversity of Arizona · US

Funding

The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI JAY A NELSON · 2017 to 2026
$24.6M
Mechanisms of Human Cytomegalovirus Latency in Primary Human Hematopoietic CellsR01AI079059 · NIAID · UNIVERSITY OF ARIZONA · PI GOODRUM, FELICIA D · 2008 to 2018
$4.4M
Mechanisms of Human Cytomegalovirus Latency in Primary Human Hematopoietic CellsR37AI079059 · NIAID · UNIVERSITY OF ARIZONA · PI Felicia D Goodrum · 2019 to 2026
$3.3M
NIAID NIH HHS P01 AI127335NIAID NIH HHS R01 AI079059NIAID NIH HHS R37 AI079059
6 · The paper itself

Abstract

Herpesvirus latency has been difficult to understand molecularly due to low levels of viral genomes and gene expression. In the case of the betaherpesvirus human cytomegalovirus (HCMV), this is further complicated by the heterogeneity inherent to hematopoietic subpopulations harboring genomes and, as a consequence, the various patterns of infection that simultaneously exist in a host, ranging from latent to lytic. Single-cell RNA sequencing (scRNA-seq) provides tremendous potential in measuring the gene expression profiles of heterogeneous cell populations for a wide range of applications, including in studies of cancer, immunology, and infectious disease. A recent study by Shnayder et al. (mBio 9:e00013-18, 2018, https://doi.org/10.1128/mBio.00013-18) utilized scRNA-seq to define transcriptomal characteristics of HCMV latency. They conclude that latency-associated gene expression is similar to the late lytic viral program but at lower levels of expression. The study highlights the numerous challenges, from the definition of latency to the analysis of scRNA-seq, that exist in defining a latent transcriptome.

Indexed as

TranscriptomeCytomegalovirusCytomegalovirus InfectionsHumansSequence Analysis, RNAVirus LatencycytomegalovirusherpesvirusesMARS-SeqscRNA-seqtranscriptome

Identifiers

PMID29895640
PMCPMC6016237
OpenAlexW2808505946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.